Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-Arm Clinical Study of Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

NCT07374003 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07374003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07374003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-Arm Clinical Study of Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 17, 2025
Completion date
December 20, 2029
Enrollment
62 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced, resectable